Table 1.

Summary of diagnostic yield of familial pancreatic cancer screening and surveillance programmes

Study	High-risk group	Imaging tests	Diagnostic yield*n (%)
Brentnall 1999 (1) n=14	FPC	EUS+ERCP+CT	7/14 (50)†
Kimmey 2002 n=46‡	FPC	EUS; ERCP§	12/46 (26)†
Canto 2004 (2) n=38	FPC, PJS	EUS; ERCP§, EUS-FNA§, CT§	2/38 (5.3)†
Canto 2006 (3) n=78	FPC, PJS	EUS; CT§,EUS-FNA§, ERCP§	8/78 (10.3)¶,†
Poley 2009 (4) n=44	FPC, BRCA, PJS, p16, p53, HP	EUS;CT§, MRI§	10/44 (23)
Langer 2009 (5) n=76	FPC, BRCA	EUS+MRCP; EUS-FNA§	1/76 (1.3)¶,†
Verna 2010 (6) n=51	FPC, BRCA, p16	EUS and/or MRCP	6/51 (12)†
Ludwig 2011 n=109	FPC, BRCA	MRCP; EUS§, EUS-FNA§	9/109 (8.3)¶
Vasen 2011 (7) n=79	p16	MRI/MRCP	14/79† (18)
Al-Sukhni 2011 (8) n=262	FPC, BRCA, PJS, p16, HP	MRI; CT§, EUS§, ERCP§	19/262¶ (7.3)
Schneider 2011 (9)** n=72	FPC, BRCA, PALB2	EUS+MRCP	11/72 (15)¶
Canto 2012 (10) n=216	FPC, BRCA, PJS	CT, MRI/MRCP, EUS; ERCP§	5/216 (2.3)†–92/216 (43)

*Yield is defined as the detection of any pathologically proven (pre)malignant lesion (≥PanIN-2/IPMN and pancreatic adenocarcinoma) and lesions that are morphologically suspicious for branch-duct IPMNs.

†Includes only pathologically proven pancreatic neoplasms (histology or cytology).

‡Continuation of Brentnall 1999, included 14 high-risk individuals from Brentnall 1999.

§Test performed only as an additional test for detected abnormalities.

¶Includes baseline and follow-up.

**Continuation of Langer 2009, includes high-risk individuals from this series.

ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonography; FNA, fine-needle aspiration; FPC, familial pancreatic cancer; IPMN, intraductal papillary mucinous neoplasm; MRCP, magnetic resonance cholangiopancreatography; PJS, Peutz–Jeghers syndrome; PanIN, pancreatic intraepithelial neoplasia.